Cambrian BioPharma Inc filed a Form D with the Securities and Exchange Commission on 2026-07-15.
Cambrian BioPharma Inc filed a Form D notice of an exempt securities offering with the SEC on July 15, 2026. The filing reports $123.75M sold. Its industry group is Biotechnology. It names James Peyer (Executive Officer, Director), Juliette Han (Executive Officer, Director), Mark Nuttall (Executive Officer) (SEC Form D, July 15, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Cambrian BioPharma Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-07-15 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Cambrian BioPharma Inc.
Free to see. No signup.
More on the people and the money behind Cambrian BioPharma Inc, from the filings we hold.
Biotechnology raises by companies based in New York, filed within 90 days of this one, largest first.
Get an email when Cambrian BioPharma Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Cambrian BioPharma Inc raises, hires or launches. No email unless you switch it on.
Watch Cambrian BioPharma Inc →Get the full cited report on Cambrian BioPharma Inc
What the filing shows about Cambrian BioPharma Inc
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Cambrian BioPharma Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Cambrian BioPharma Inc's address as 228 Park Avenue South, Suite 66643, New York, NY 10003.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Cambrian BioPharma Inc →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Cambrian BioPharma Inc is a registered filer with the SEC (CIK 1797409) and has filed since 2023-12-22. 2 filings are on record, the latest on 2026-07-15.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Cambrian BioPharma Inc's Form D of 2026-07-15 names James Peyer, Juliette Han, Mark Nuttall and 8 more as its officers, directors or promoters.
Its new offerings report $131.44M sold across 2 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 771 filings in Biotechnology, totalled by week. The dot is this raise, $123.75M, on the same scale — one filing against the whole group's total, so it sits low by construction.
James Peyer is named as Executive Officer and Director on the Form D that Cambrian BioPharma Inc filed with the SEC on 15 July 2026, one of 11 people that filing names.
Juliette Han is named as Executive Officer and Director on the Form D that Cambrian BioPharma Inc filed with the SEC on 15 July 2026, one of 11 people that filing names.
Mark Nuttall is named as Executive Officer on the Form D that Cambrian BioPharma Inc filed with the SEC on 15 July 2026, one of 11 people that filing names.
Ruth Thieroff-Ekerdt is named as Executive Officer on the Form D that Cambrian BioPharma Inc filed with the SEC on 15 July 2026, one of 11 people that filing names.
William DeVaul is named as Executive Officer on the Form D that Cambrian BioPharma Inc filed with the SEC on 15 July 2026, one of 11 people that filing names.
Christian Angermeyer is named as Director on the Form D that Cambrian BioPharma Inc filed with the SEC on 15 July 2026, one of 11 people that filing names.
Maryanna Saenko is named as Director on the Form D that Cambrian BioPharma Inc filed with the SEC on 15 July 2026, one of 11 people that filing names.
Brenton Saunders is named as Director on the Form D that Cambrian BioPharma Inc filed with the SEC on 15 July 2026, one of 11 people that filing names.
Paul Farr is named as Director on the Form D that Cambrian BioPharma Inc filed with the SEC on 15 July 2026, one of 11 people that filing names.
Martin Gunhaga is named as Director on the Form D that Cambrian BioPharma Inc filed with the SEC on 15 July 2026, one of 11 people that filing names.
Lorin Van Nuland is named as Director on the Form D that Cambrian BioPharma Inc filed with the SEC on 15 July 2026, one of 11 people that filing names.
11 people named on the filing — 5 holding an executive role and 6 as directors only.
Named as of the 2026-07-15 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Cambrian BioPharma Inc
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Cambrian BioPharma Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cambrian BioPharma Inc covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Cambrian BioPharma IncYou get an alert in MentionFox the next time this company shows up.
If you're behind Cambrian BioPharma Inc: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Cambrian BioPharma Inc. With no account yet, you sign up free and land on the result.
On these lists: New York raises, week of 2026-07-13 · Biotech raises, week of 2026-07-13 · Biotech raises in New York
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/cambrian-biopharma-inc-form-d-26000001